Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varegacestat in Hepatic Impairment
NCT06841315Phase 1Completed
- Sponsor
- Immunome
- Start
- Mar 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of varegacestat in desmoid tumor (4 arms), sponsored by Immunome. Primary endpoints: Pharmacokinetics of varegacestat at 4 weeks and Pharmacokinetics of metabolite at 4 weeks. Started Mar 2025; status: completed.
02
Drugs
varegacestat
03
Conditions
desmoid tumor
Beyond the preview
Go deeper on NCT06841315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06841315.